Neutralization of terminal differentiation in gliomagenesis by Hu,  J. et al.
Neutralization of terminal differentiation
in gliomagenesis
Jian Hua,b, Allen L. Hoa,b,c, Liang Yuana,b, Baoli Hua,b, Sujun Huaa,b, Soyoon Sarah Hwanga,b, Jianhua Zhangb,d,
Tianyi Hue, Hongwu Zhengf, Boyi Gang, Gongxiong Wuh, Yaoqi Alan Wanga,b, Lynda Chinb, and Ronald A. DePinhoa,1
Departments of aCancer Biology, bGenomic Medicine, and gExperimental Radiation Oncology and dInstitute of Applied Cancer Science, University of Texas
MD Anderson Cancer Center, Houston, TX 77030; cHarvard Medical School, Boston, MA 02115; eTrinity College of Arts and Sciences, Duke University, Durham,
NC 27708; fCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724; and hJoslin Diabetes Center, Harvard Medical School, Boston, MA 02115
This article is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected in 2012.
Edited by Douglas Hanahan, University of California, San Francisco, CA, and approved July 11, 2013 (received for review May 8, 2013)
An immature state of cellular differentiation—characterized by stem
cell–like tendencies and impaired differentiation—is a hallmark of
cancer. Using glioblastoma multiforme (GBM) as a model system,
we sought to determine whether molecular determinants that
drive cells toward terminal differentiation are also genetically tar-
geted in carcinogenesis and whether neutralizing such genes also
plays an active role to reinforce the impaired differentiation state
and promote malignancy. To that end, we screened 71 genes with
known roles in promoting nervous system development that also
sustain copy number loss in GBM through antineoplastic assay and
identiﬁed A2BP1 (ataxin 2 binding protein 1, Rbfox1), an RNA-
binding and splicing regulator that is deleted in 10% of GBM cases.
Integrated in silico analysis of GBM proﬁles to elucidate the
A2BP1 pathway and its role in glioma identiﬁed myelin transcrip-
tion factor 1-like (Myt1L) as a direct transcriptional regulator of
A2BP1. Reintroduction of A2BP1 or Myt1L in GBM cell lines and
glioma stem cells profoundly inhibited tumorigenesis in multiple
assays, and conversely, shRNA-mediated knockdown of A2BP1 or
Myt1L in premalignant neural stem cells compromised neuronal
lineage differentiation and promoted orthotopic tumor formation.
On the mechanistic level, with the top-represented downstream tar-
get TPM1 as an illustrative example, we demonstrated that, among
its multiple functions, A2BP1 serves to regulate TPM1’s alternative
splicing to promote cytoskeletal organization and terminal dif-
ferentiation and suppress malignancy. Thus, in addition to the
activation of self-renewal pathways, the neutralization of genetic
programs that drive cells toward terminal differentiation may also
promote immature and highly plastic developmental states that
contribute to the aggressive malignant properties of GBM.
oncogenomics | cancer stem cells
In cancer, the bases of classical biological hallmarks such asaberrant cell cycle control or apoptosis resistance are brought
about and reinforced by multiple genetic events governing such
processes (1). These cooperative genetic events in the same
cancer cell typically involve both the activation of positive drivers
and inactivation of suppressive factors needed to commandeer
the redundant genetic controls underlying all biological pro-
cesses present in normal cells. For example, deregulated cell
cycle control in cancer often involves the cooperative impact of
activation of D-type cyclins and loss of G1 cyclin–dependent
kinase inhibitors in the same cancer cell (2).
A hallmark of cancer is the acquisition of a cellular differenti-
ation state typiﬁed by maintenance of stem cell–like properties that
maintain robust renewal activity and capacity to generate differ-
entiated progeny, albeit with profound impairment in terminal
differentiation. Substantial evidence has established that this highly
de-differentiated and plastic state reﬂects acquisition of genetic
events that actively promote stemness, such as activation of WNT,
Shh, and Notch signaling pathways (3). Glioblastoma multiforme
(GBM), the most common and lethal primary brain tumor in adults
(4, 5), possesses both glioma stem cells (GSCs) (6–12) and more
differentiated tumor cells, which manifest as signiﬁcant morpho-
logical heterogeneity characterized by immature glial and neuronal
features (4, 13–15). Current evidence has established that the GSC
state is driven in part by WNT and Myc (16–18), which promote
stemness yet allow for partial cellular differentiation capacity,
a process thought to fuel cellular heterogeneity in GBM (13, 15).
In this study, we sought to answer whether loss of terminal dif-
ferentiation capacity simply reﬂects acquisition of enhanced self-
renewal capability of GSCs or whether the genes that drive cells
toward terminal differentiation are also actively neutralized through
mutations/genomic alterations, and if so, whether such genetic
events are essential in gliomagenesis.
Results
The differentiation hierarchy of human GBM is readily evidenced
by stem, progenitor, and cell differentiation marker proﬁles of a
panel of human GBM tissue microarray (TMA) samples (n = 71),
revealing moderate to high levels of the neural stem cell marker
Nestin, as well as more committed progenitor markers for astro-
cytes (GFAP), oligodendrocytes (Olig2), and neurons (Tuj1 and
Dcx) (Fig. 1A). In sharp contrast, fewer GBMcells express terminal
differentiated cell markers for oligodendrocytes (MBP) and neu-
rons (NeuN) (Fig. 1A). In addition, GBM cells that express ter-
minal differentiated astrocyte marker S-100β are also signiﬁcantly
fewer than the cells that express progenitor astrocyte maker
GFAP (Fig. 1A). Together, this proﬁle of differentiation markers
reveals marked cellular heterogeneity dominated by an immature
state of cell differentiation. Notably, the level of heterogeneity
positively correlates with grades of glioma, which is reﬂected by
an increased cell population of neuronal lineage in high-grade
glioma (SI Appendix, Fig. S1). The cells of neuronal lineage in
GBM are indeed tumor cells instead of normal cells trapped
among tumor cells, because they express proliferating GBM cell
marker Ki67 and a high level of EGFR (SI Appendix, Fig. S2).
In an effort to identify genetic events that may drive de-
activation of terminal differentiation capacity, we surveyed The
Cancer Genome Atlas (TCGA) GBM dataset for genes showing
both recurrent copy number loss (GISTIC) (19, 20) and pos-
sessing known roles in promoting nervous system development
(ingenuity pathway analysis and PubMed). The ORFs of 71
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genes that scored in both categories (SI Appendix, Table S1)
were transduced individually into the GBM cell line LN319 and
audited for anchorage-independent activity in the soft agar assay,
which reﬂects both cell renewal and malignant potential. One of
the 71 genes, A2BP1, caused marked reduction in soft agar
colony formation of LN319 cells (SI Appendix, Fig. S3). A2BP1 is
an alternative splicing factor that functions in neural develop-
ment, and its genomic alterations have been implicated with
several neurodevelopmental and neuropsychiatric disorders in-
cluding autism spectrum disorder (ASD) (21). A2BP1 encodes
both cytoplasmic and nuclear isoforms (Fig. 1 B and C), and the
antioncogenic activity of both A2BP1 isoforms was also docu-
mented with soft agar colony formation and s.c. tumor growth in
an additional GBM cell line: U373 (Fig. 1 D–G). Notably, the
nuclear isoform showed more potent soft agar and s.c. growth
inhibition than the cytoplasmic isoform (Fig. 1 D–G).
The copy number proﬁling of 430 TCGA GBM tumor samples
(TCGA, Firehose 5/25/2011) shows that A2BP1 is deleted in
10% of GBM tumor samples (Fig. 1H). Furthermore, immuno-
histochemistry (IHC) analysis showed that the A2BP1 protein is
absent or down-regulated in >90% of GBM tumor TMA sam-
ples (Fig. 1I). Besides GBM, A2BP1 is also deleted in other
nervous system tumors, including ∼26% of neuroblastomas and
18% of medullablastomas (22) (TCGA). Additionally, deletion
of A2BP1 in 48% of colon cancer samples and 18% of sarcoma
(22) samples suggests a major tumor suppressor function across
multiple cancer types (TCGA).
A2BP1 is expressed exclusively in differentiated neurons as
documented by costaining of A2BP1 and the mature neuronal
cell marker NeuN, as well as pan-neuronal cell marker Tuj1
(labels both progenitor and mature neurons) and by lack of
costaining of A2BP1 and stem cell markers Msi-1 and BLBP,
astrocyte markers GFAP and ALDH1L1, oligodendrocyte mark-
ers Olig2, NG2, and A2B5, and neuronal progenitor cell marker
Dcx (SI Appendix, Fig. S4). Costaining with α-BrdU and
α-A2BP1 antibodies of actively developing brains (2-wk-old
postnatal mice injected with BrdU) revealed no overlap, in-
dicating restriction of A2BP1 expression in postmitotic termi-
nally differentiated neurons (Fig. 2A). We then sought to test
whether A2BP1 controls the terminal differentiation of NSCs by
taking advantage of premalignant neural/progenitor stem cells
(PM-NSCs) derived from p53L/L Pten+/L GFAP-Cre mice, which
maintain full neuronal lineage differentiation capability (18).
On placement in ENStem-A neuronal differentiation medium,
Fig. 1. A2BP1 is a tumor suppressor that is deleted and down-regulated in GBM. (A) Protein expression proﬁles of various stem cell and lineage markers in
human GBM. (B) Localizations of A2BP1 nuclear and cytoplasmic isoforms shown with immunoﬂuorescence (IF). (C) Expression levels of ectopic A2BP1 nuclear
and cytoplasmic isoforms shown with immunoblotting. (D) Representative images of anchorage independent soft agar growth of LN18 and U373 cells
expressing nuclear and cytoplasmic isoforms of A2BP1. (E) Statistical analysis of D. *P < 0.001, **P < 0.0001. (F) Representative images of s.c. tumor formation
of U373 cells expressing nuclear and cytoplasmic isoforms of A2BP1. (G) Statistical analysis of F. (H) IGV representation of deletion of A2BP1 locus in GBM. (I)
Representative IHC images of A2BP1 in GBM samples and WT brain tissues. (Scale bars, 100 μm.) Error bars indicate SD.
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A2BP1 knockdown by independent shRNAs (shA2BP1s) (SI
Appendix, Fig. S5 A and B) led to marked reduction in the
neuronal terminal differentiation marker NeuN and increase of
BrdU incorporation and Dcx+ neuroblast cell population (Fig. 2
B and C; SI Appendix, Figs. S5 C–E and S7 A and B), yet exerted
no impact on the pan-neuronal cell marker Tuj1 and MAP2
staining relative to nontargeting shRNA (shNT) control (SI
Appendix, Figs. S5 F and G and S7 A and B). Under stem cell
medium (SCM) conditions, shA2BP1 does not inﬂuence ex-
pression of the NSC marker Nestin (SI Appendix, Figs. S5 F and
G and S7 A and B) or neurosphere formation (SI Appendix, Figs.
S6 and S7C) relative to shNT control, further supporting that the
A2BP1 shRNAs only operate in a more differentiated cell con-
text. Notably, shA2BP1 also had no impact on the capacity for
astrocytic differentiation of PM-NSCs cultured in astrocytic dif-
ferentiation medium (1% FBS) (SI Appendix, Figs. S5 F and G
and S7 A and B). Similarly, using the P19 embryonal carcinoma
model system, A2BP1 knockdown in prodifferentiation conditions
(retinoic acid) results in decreased NeuN-positive cell numbers
and exerts no differences in Tuj1- and GFAP-positive cell
numbers relative to shNT control (SI Appendix, Fig. S8 A and B).
Thus, we conclude that A2BP1 plays a lineage-restricted, dif-
ferentiation-speciﬁc role in promoting the terminal differentia-
tion of neuronal lineage (Fig. 2 B and C).
The p53−/− Pten+/− PM-NSCs do not form tumors on orthotopic
injection into the mouse brain (see below). To assess whether com-
promised neuronal terminal differentiation affected by A2BP1
extinction enhances gliomagenesis, p53−/− Pten+/− PM-NSCs
transduced with shA2BP1 or shNT were implanted orthotopically
and monitored for tumor formation. The shA2BP1 cohort gen-
erated brain tumors commencing at 15 wk, whereas PM-NSCs
expressing shNT remained tumor free through 25 wk of obser-
vation (Fig. 2 D and E). Similarly, A2BP1 knockdown also sig-
niﬁcantly decreased the latency of intracranial tumor formation
of P19 cells (SI Appendix, Fig. S8C). Histological analysis revealed
that p53−/− Pten+/−-shA2BP1 orthotopic tumors express neuronal
Fig. 2. Loss of A2BP1 contributes to GBM tumorigenesis by causing compromised terminal differentiation. (A) Colocalization of A2BP1 and proliferation
marker BrdU in mouse brain tissue shown with IF. (B) Representative IF staining of A2BP1 and NeuN in p53−/−Pten+/− premalignant neural stem cells (PM-NSCs)
with A2BP1 knockdown or control shRNA cultured in stem cell medium (SCM) and neuronal differentiation medium EN-StemA. (C) Statistical analysis of
staining of A2BP1, NeuN, and Dcx in p53−/−Pten+/− PM-NSCs with A2BP1 knockdown or control shRNA cultured in SCM and EN-StemA medium. *P < 0.0001
compared with shNT controls. (D) Representative H&E staining of intracranial tumor formation of p53−/−Pten+/− PM-NSCs with A2BP1 knockdown or control
shRNA. (E) Kaplan–Meier survival curves (log-rank test) of mice intracranially injected with p53−/−Pten+/− PM-NSCs with A2BP1 knockdown or control shRNA.
(F) Representative IF staining of cleaved caspase3 in p53−/−Pten−/− GSCs with A2BP1 overexpression or mock cultured in SCM and EN-StemA medium. (G)
Statistical analysis of F. (H) Representative H&E staining of intracranial tumor formation of p53−/−Pten−/− GSCs with A2BP1 overexpression or mock. (I) Kaplan–
Meier survival curves (log-rank test) of mice intracranially injected with p53−/−Pten−/− GSCs with A2BP1 overexpression or mock. (Scale bars, 2 mm.) *P <
0.0001, **P = 0.03. Error bars indicate SD.
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progenitor cell markers Tuj1 and Dcx, stem/progenitor cell marker
Nestin, and astrocyte marker GFAP (SI Appendix, Fig. S9), sug-
gesting that extinction of factors driving terminal differentiation
can promote glioma tumors that exhibit a highly plastic and
immature developmental state with varied lineage representa-
tion. To further verify the impact of A2BP1 on differentiation
and tumorigenic potential, A2BP1 was overexpressed in p53−/−
Pten−/− GSCs derived from gliomas arising in p53L/L Pten+/L
GFAP-Cre mice (18). Although enforced expression of A2BP1
had no impact on GSCs maintained in stem cell medium, in-
duction of neuronal differentiation in the setting of enforced
A2BP1 expression resulted in increased cell death in neuronal
lineage (Fig. 2 F and G; SI Appendix, Fig. S10 A–D). Supporting
the function of A2BP1 in promoting terminal differentiation of
neurons, ectopic expression of A2BP1 in NSCs increased NeuN/
Synapsin double positive cell population in neuronal differentia-
tion medium (SI Appendix, Fig. S10 E and F). Correspondingly,
enforced A2BP1 expression also impaired tumor formation fol-
lowing orthotopic implantation of both mouse and human GSCs
(Fig. 2 H and I; SI Appendix, Fig. S11). IF (immunoﬂuorescence)
costaining showed that a signiﬁcant fraction (60%) of A2BP1-
associated apoptosis occurred in the neuronal lineage, but only
minimal apoptosis occurred in GSCs and the astrocytic lineage
(SI Appendix, Fig. S12 A and B), whereas A2BP1 expression was
induced equally in all cell populations (SI Appendix, Fig. S12C)
of xenograft tumors derived from p53−/− Pten−/− GSCs.
If neutralization of neuronal terminal differentiation is indeed
required for gliomagenesis, we next asked whether other genetic
components in the A2BP1 pathway are impacted in those GBMs
with genomic retention of the A2BP1 locus. Because A2BP1
expression is suppressed in greater than 90% of the GBM sam-
ples yet deleted in only 10% of cases, we focused on the iden-
tiﬁcation of potential transcriptional regulators of A2BP1 and
assessed their genomic status by ﬁrst correlating expression of
A2BP1 with all other genes in the transcriptomic dataset of 537
TCGA tumor samples (TCGA, Firehose 5/25/2011). Myt1L was
the top transcription factor whose expression levels positively
correlate with A2BP1 expression levels in GBM (R2 = 0.647; Fig.
3A). Myt1L was found to be deleted in about 5% of GBM
samples in a mutually exclusive manner with A2BP1 deletion
(P < 0.01; Fig. 3B), and IHC analysis of GBM TMAs showed
that the Myt1L protein is absent or down-regulated in >80% of
samples (SI Appendix, Fig. S13A). Notably, Myt1L is one of the
ingredients of the transcription factor mixture that can trans-
differentiate ﬁbroblasts into mature neurons (23–27). Using
α-Myt1L CHIP-seq and conﬁrmatory CHIP-PCR in mouse brain
extracts, Myt1L was shown to bind to four distinct sites within
two A2BP1 promoters (Fig. 3 C and D). Luciferase reporter
assays showed that both A2BP1 promoter sequences, but not
three control sequences, were strongly activated by enforced
Myt1L expression (Fig. 3E).
To dissect the functions of Myt1L, we did Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis on 258 genes
(SI Appendix, Table S2) with Myt1L binding sites within 10 kb
from the transcription start site identiﬁed by CHIP-seq and
found overrepresentation of genes regulating multiple biological
functions including metabolism, cellular assembly and organi-
zation, and nervous system development (SI Appendix, Table
S3), which partially overlap with the functions assigned to A2BP1
(SI Appendix, Table S5). Next, we sought to assess whether
Myt1L exerts tumor suppressive and proneuronal differentiation
activities similar to A2BP1. Enforced Myt1L expression in p53−/−
Pten−/− GSCs increased cell death in the neuronal differenti-
ation medium and exerted no impact on the survival of GSCs in
astrocytic differentiation medium (SI Appendix, Fig. S13B) nor
affected the self-renewal activity of GSCs maintained in stem cell
medium (SI Appendix, Fig. S13 C and D). In addition, enforced
Myt1L expression in GSCs inhibited orthotopic tumor formation
(Fig. 3 F and G). Supporting the function of Myt1L in promoting
neuronal terminal differentiation, enforced Myt1L expression in
NSCs increased NeuN/Synapsin double positive cell population
in neuronal differentiation medium (SI Appendix, Fig. S13 E
and F). shRNA-mediated knockdown of Myt1L by two in-
dependent hairpins in p53−/−Pten+/− PM-NSCs reduced NeuN+
cell numbers and increased BrdU incorporation in neuronal
differentiation medium (SI Appendix, Fig. S13 G and H) and
induced orthotopic tumor formation at 15 wk, whereas shNT
controls remained tumor free through 25 wk of observation (Fig.
3 H–J). Finally, to further substantiate the Myt1L–A2BP1 axis in
gliomagenesis, we asked whether Myt1L inhibits tumorigenesis
in part via A2BP1. A2BP1 knockdown signiﬁcantly restored the
soft agar formation reduced by ectopic Myt1L in neuronal dif-
ferentiation medium (Fig. 3 K and L; SI Appendix, Fig. S14A),
and ectopic A2BP1 signiﬁcantly decreased soft agar and tumor
formation induced by Myt1L knockdown (SI Appendix, Fig.
S14B–E). Together, these epistasis studies support the view
that A2BP1 is at least partly involved in Myt1L-dependent glioma
suppression and control of neuronal differentiation but also
point to nonoverlapping functions of A2BP1 and Myt1L in
these processes.
The potent antioncogenic activity of the A2BP1 nuclear iso-
form and the known role of this isoform in regulating alternative
splicing (28) prompted us to comprehensively proﬁle A2BP1
interactions with RNAs in an effort to fully understand the role
of A2BP1 in neuronal differentiation and tumor suppression. To
that end, A2BP1 protein–RNA complexes were immunopreci-
pitated from normal mouse brains with RNA-binding protein
immunoprecipitation-microarray (RIP)-Chip protocol (29), and
the associated RNAs were identiﬁed by exon array proﬁling (SI
Appendix, Fig. S15A). The cutoff of fourfold enrichment by
α-A2BP1 IP vs. control IgG IP identiﬁed A2BP1-associated
mRNAs expressed by 2,464 genes. Examination of these genes
for the well-characterized A2BP1’s binding motif (UGCAUG)
(30, 31) within intronic 300 bp from the splicing site identiﬁed
7,061 putative targets of A2BP1 that are conserved between
mouse and human (SI Appendix, Fig. S15B). Integration of
A2BP1-associated RNAs identiﬁed by RIP-Chip and the genes
with A2BP1 binding motifs identiﬁed in silico yielded a list of 906
genes potentially regulated by A2BP1 (SI Appendix, Fig. S15B
and Table S4). KEGG pathway analysis identiﬁed 53 pathways
signiﬁcantly (P < 0.05) enriched in these A2BP1 targets (SI
Appendix, Table S5). Sixty-three percent of these pathways be-
long to four major functions: cytoskeletion regulation (21%),
neural development (11%), metabolism (21%), and signaling
(15%). To check whether the antioncogenic activity of A2BP1 is
governed in part through the alternative splicing of its targets
identiﬁed in normal neural tissues, we focused on TPM1 as a
working model because TPM1 was found to be the most en-
riched transcript (40- to 50-fold; Fig. 4A) in the α-A2BP1
immunoprecipates relative to IgG control.
TPM1 is an actin-binding protein (32), which belongs to the
cytoskeleton regulation pathways. It has two UGCAUG binding
motifs within the 200 bp ﬂanking exons 6a and 6b, which are
spliced mutually exclusively (33). EMSA conﬁrmed that re-
combinant A2BP1 protein binds to in vitro transcribed TPM1
exon 6a and 6b fragments, and the stability of these nucleo-
protein complexes is dependent on the presence of intact
UGCAUG binding motifs (SI Appendix, Fig. S15C). To test
whether A2BP1 regulates the splicing of TPM1 exon 6a and 6b,
we overexpressed nuclear and cytoplasmic isoforms of A2BP1 in
GBM cell line LN18. Although the cytoplasmic isoform did not
alter TPM1 splicing, the nuclear isoform signiﬁcantly increased
the generation of exon 6b–containing transcripts (Fig. 4B; SI
Appendix, Fig. S15D), which is consistent with the enrichment of
exon 6b in PM-NSCs cultured in neuronal differentiation me-
dium (SI Appendix, Fig. S15E). In addition, knockdown of
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A2BP1 also reduced exon 6b–containing transcripts in neuro-
nal differentiated PM-NSCs (Fig. 4C). To check whether A2BP1
expression levels correlate with the relative expression of exon 6b
vs. 6a, we took advantage of the exon array dataset of 194 TCGA
GBM samples (20). Polynomial regression analysis (K = 3)
showed a signiﬁcant positive correlation between A2BP1 ex-
pression levels and the relative expression ratios of exon 6b/exon
6a (Fig. 4D; R2 = 0.4335), supporting that the mutually exclusive
splicing of TPM1 exon 6a/6b regulated by A2BP1 also occurs in
the human GBM context.
TPM1 is a well-established tumor suppressor, and the down-
regulation of TPM1 and the resulting cytoskeletal reorganiza-
tion are indispensable for Ras- and Src-mediated transformation
(33–40), prompting us to assess whether switching TPM1 exon
6a to 6b will also have antioncologic effect. We ectopically
expressed TPM1-6a (TM3) or TPM1-6b (TM2) in LN18 cells
(SI Appendix, Fig. S15F), which were subsequently assessed in
an array of cancer-relevant assays. TPM1-6b, but not TPM1-
6a, resulted in signiﬁcantly reduced soft agar colony formation
and decreased invasive and migratory activity (Fig. 4 E–G).
Consistent with the impact on cytoskeleton and cellular motility,
analysis of focal adhesion marker Vinculin and stress ﬁber marker
Phalloidin staining patterns showed that LN18 cells expressing
TPM1-6b have signiﬁcantly more focal adhesion sites and
a higher order of stress ﬁbers relative to cells expressing TPM1-6a
or mock (Fig. 4 H and I). In line with A2BP1’s role in terminal
differentiation, ectopic TPM1-6a but not 6b increased BrdU
incorporation and decreased NeuN-positive cells in PM-NSCs
(SI Appendix, Fig. S16 A and B). Finally, TMP1-6b–expressing
cells but not TPM1-6a–expressing cells showed potent inhibition
Fig. 3. Myt1L is a transcription factor that directly regulates A2BP1 expression under neural/glioma stem cell context. (A) Plotted correlation between A2BP1
expression levels and Myt1L expression levels in human GBM samples. (B) IGV representation of deletion of Myt1L locus in GBM. (C) Enrichment of Myt1L
binding sequences (black bars) in two A2BP1 promoters identiﬁed with CHIP-Seq. (D) Veriﬁcation of Myt1L binding sequences of A2BP1 promoters by CHIP-
PCR with multiple sequences. L and S, A2BP1 promoters driving expressions of long and short transcripts, respectively. (E) Luciferase assay of A2BP1 promoters
with overexpression of Myt1L or mock. L and S, A2BP1 promoters driving expression of long and short transcripts, respectively *P < 0.0001 compared with
controls. (F) Representative images of intracranial tumor formation of p53−/−Pten−/− GSCs with Myt1L overexpression or mock. (G) Kaplan–Meier survival
curves (log-rank test) of mice with intracranial injection of p53−/−Pten−/− GSCs with Myt1L overexpression or mock. (H) Knockdown of Myt1L in p53−/−Pten+/−
PM-NSCs with shMyt1L or control shRNAs. *P < 0.0001 compared with mock or shNT controls. (I) Representative images of intracranial tumor formation of
p53−/−Pten+/− PM-NSCs with shMyt1L or control shRNA. (J) Kaplan–Meier survival curves (log-rank test) of mice with intracranial injection of p53−/−Pten+/−
PM-NSCs with shMyt1L or control shRNA. (K) Representative images of anchorage independent soft agar growth of p53−/−Pten+/− PM-NSCs with Myt1L
overexpression with/without A2BP1 knockdown in EN-stemA medium. (L) Statistical analysis of K. (Scale bars, 50 μm.) *P < 0.001, **P < 0.0001. Error bars
indicate SD.
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of s.c. tumor growth (Fig. 4 J and K). Supporting that A2BP1
inhibits gliomagenesis partly through regulating TPM1 alterna-
tive splicing, only ectopic TPM1-6b but not 6a signiﬁcantly
suppressed intracranial tumor formation induced by A2BP1
knockdown (SI Appendix, Fig. S16 C and D). Thus, although
A2BP1 is likely to suppress gliomagenesis through regulation of
many genes (SI Appendix, Tables S4 and S5), these studies
identify one key mechanism underlying A2BP1’s tumor sup-
pression activity via the control of TPM1 splicing isoforms in
GBM cells.
Discussion
This work demonstrates that neutralization of the terminal dif-
ferentiation program governed by the Myt1L–A2BP1 axis can
contribute to gliomagenesis via cell autonomous mechanisms,
although we cannot formally rule out additional non–cell auton-
omous effects of loss of Myt1L–A2BP1. These ﬁndings strongly
support the concept that the promotion of an immature differ-
entiation state in cancer is driven both by activation of pathways
promoting cancer stemness and neutralization of those inducing
terminal differentiation. That Myt1L–A2BP1 are major regulators
in neoplastic differentiation processes in glioma is reinforced by
the known potent transdifferentiation potential of Myt1L in
neuron generation (23–27), the capacity of Myt1L to directly
regulate A2BP1 transcription but not the A2BP1 paralogs Rbfox2
and Rbfox3 (SI Appendix, Table S2), the failure of Rbfox2/3 to
rescue loss of the Myt1L–A2BP1 axis in tumorigenesis assays, and
the tumorigenic impact of alternative splicing of a key A2BP1
target regulating cytoskeletal dynamics. Indeed, although our
unbiased survey of A2BP1 targets identiﬁed its pleiotropic func-
tionality in neural development, A2BP1’s regulation of cytoskel-
etal conﬁguration during the neuronal terminal differentiation
emerged as one of its prominent activities. In addition, low ex-
pression of A2BP1 is enriched in mesenchymal subtype, and the
A2BP1 level is relatively higher in the proneural and neural
subtypes (TCGA, P < 0.001). These ﬁndings are consistent with
the importance of loss of cellular polarity and cell–cell adhesion,
Fig. 4. A2BP1 regulates alternative splicing of exons 6a and 6b of TPM1. (A) RT-QPCR quantiﬁcation of TPM1 mRNA associated with A2BP1 immunopre-
cipitated with anti-A2BP1 antibody in mouse brain. *P < 0.0001. (B) Alternative splicing of TPM1 exons 6a and 6b in LN18 cells with ectopic expression of
A2BP1 nuclear or cytoplasmic isoforms or mock was shown with PCR. (C) Alternative splicing of TPM1 exons 6a and 6b in p53−/−Pten+/− PM-NSCs with A2BP1
knockdown and control shRNA in neuronal differentiation medium EN-StemA was shown with PCR. (D) Plotted correlation between A2BP1 expression levels
and relative expression levels of TPM1 exon 6b vs. 6a in GBM samples. (E) Anchorage independent soft agar growth of LN18 cells with ectopic expression of
TPM1-6a, TPM1-6b, or mock. *P < 0.01 compared with mock or TPM1-6a. (F) Wound healing assay of LN18 cells with ectopic expression of TPM1-6a, TPM1-6b,
or mock. *P < 0.001 compared with mock or TPM1-6a. (G) Invasion chamber assay of cells with ectopic expression of TPM1-6a, TPM1-6b, or mock. *P < 0.001
compared with mock or TPM1-6a. (H) Representative images of focal adhesion sites and stress ﬁber of cells with ectopic expression of TPM1-6a, TPM1-6b, or
mock were shown with IF. (I) Statistical analysis of H. (J) Representative images of s.c. tumor formation of cells with ectopic expression of TPM1-6a, TPM1-6b,
or mock were shown with IF. (K) Statistical analysis of J. Error bars indicate SD.
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deregulated cytoskeletal dynamics, and enhanced cell motility in
cancer, and represent a prominent phenotype typiﬁed by the
epithelial–mesenchymal transition (EMT) phenomenon (41, 42).
EMT-like cytoskeletal conﬁguration changes have also been
documented in diverse solid tumors including GBM (43, 44).
Our study shows that loss of the Myt1L–A2BP1 axis can promote
a gliomagenesis-prone cytoskeletal state through modulating
alternative splicing of multiple cytoskeleton regulators including
actin regulator TPM1.
GBM exhibits striking intratumoral heterogeneity, which may
establish critical homotypic and heterotypic interactions across
many cell types to form a cancerous community (13). Disease
heterogeneity resides, not only in inter- and intratumoral geno-
mic proﬁles (45–47), but also in the profound variability in cel-
lular differentiation state of cancer cells. This genomic and
biological variability has therapeutic implications as the state of
differentiation is known to inﬂuence the function of speciﬁc
genes and may therefore determine whether a drug target
remains rate limiting for tumor maintenance. This principle is
evident by the ﬁnding that enforced A2BP1 expression had no
impact under stem cell conditions yet provoked apoptosis on
differentiation (Fig. 2F; SI Appendix, Fig. S7).
Our work supports the view that the cellular heterogeneity and
“multiforme” histological features deﬁned by various differenti-
ation states are contributed by the remaining intermediate dif-
ferentiation capacities of GSCs and maintained by compromised
terminal differentiation capability. Loss of terminal differentia-
tion with a defective Myt1L–A2BP1 axis might explain the mini-
mal impact of differentiation therapy (such as retinoic acid) in
GBM, particularly in those cancers with genomic loss of these
key prodifferentiation regulators (48, 49). Notably, other than
genomic loss in 5% of GBM samples, mechanisms of Myt1L
silencing in the majority of the GBM samples currently remain
unclear. On the basis of our ﬁndings, we speculate that agents
targeting both neutralization of stemness pathways (e.g., WNT)
and activation of Myt1L–A2BP1-directed terminal differentia-
tion may provide a more effective therapeutic approach in GBM.
Besides neuronal lineage, compromised terminal differentiation
of other lineages including astrocyte and oligodendrocyte is also
observed in GBM (Fig. 1A; SI Appendix, Fig. S1). Similar ap-
proaches as described in this study can be used to identify key
players driving terminal differentiation of the glial lineage in the
context of gliomagenesis.
Materials and Methods
Mice. p53L, PtenL, and hGFAP-Cre mice have been described previously (18),
and were interbred and maintained on a FvB/C57Bl6 hybrid background in
pathogen-free conditions at the Dana-Farber Cancer Institute and MD
Anderson Cancer Center, monitored for signs of ill health every other
day, and euthanized and necropsied when moribund. All manipulations
were performed with Institutional Animal Care and Use Committee
(IACUC) approval.
Histology and Antibodies. Once killed, mice were perfused with 4% (wt/vol)
paraformaldehyde (PFA), and brains were dissected, followed by overnight
postﬁxation in 4% PFA at 4 °C. Serial sections were prepared at 5 μm for
parafﬁn sections or 10 μm for cryostat sections, with every 10th slide stained
by H&E (DF/HCC Research Pathology Cores). Primary antibodies used for IHC,
IF, and immunoblotting are Gfap (Z0334; DAKO), Gfap (556330; BD Phar-
mingen), Nestin (MAB353; Chemicon; speciﬁcally for mouse), Nestin (MAB5326;
Chemicon; speciﬁcally for human), Olig-2 (AB9610; Chemicon), Tuj-1 (MMS-
435P; Covance), O4 (MAB1326; R&D), NeuN (MAB377; Millipore), Mbp (ab7349;
Abcam), MAP2 (AB5622; Millipore), Phalloidin (Invitrogen), Vinculin (V4505 and
V9131; Sigma), Caspase3 (Asp175) (9661; Cell Signaling), Dcx (ab18723;
Abcam), BrdU (DAKO), S100 (RB044A0; LabSource), α-tubulin (T-9026; Sigma),
V5 (Invitriogen), A2BP1 (N14) (Santa Cruz), A2BP1 (Genescript, against peptide
sequence MAQPYASAQFAPPQN), A2BP1 (rat monoclonal antibodies; Dana
Farber Monoclonal Antibody facility), Myt1L (AB093283; Abnova), and
TPM1 (NB100-1908; Novus Biologicals).
Human GBM IHC Staining Grading. Human GBM samples were stained with
GFAP, S-100β, Olig2, MBP, Tuj1, Dcx, NeuN, and Nestin antibodies. Samples
with >50%, 5–50%, and <5% positive cells were categorized as high, me-
dium, and low, respectively.
Bioinformatic Approach to Get Candidate Genes Involved in Both Differentiation
and Tumorigenesis. The GISTIC algorithm was described previously (19). Brieﬂy,
deleted genes were deﬁned by genes residing in regions that are deleted in>5%
of GBM samples and contain <50 genes. Genes in nervous system development
were selected by integration of ingenuity pathway analysis (IPA) and PubMed.
Cell Culture. The human glioma cell lines U373, LN18, and LN319 and the
human embryonic kidney cell line HEK293T were purchased from American
Type Culture Collection (ATCC) and maintained in DMEM containing 10%
(vol/vol) FBS. The human GSC line TS603 was from Cameron Brennan of
Memorial Sloan-Kettering Cancer Center (New York, NY).
Primary mouse PM-NSCs and GSCs were isolated from the brain sub-
ventricular zone (SVZ) of E13.5 mouse embryos and mouse brain tumors with
the indicated genotypes as previously described, respectively (17, 18). PM-
NSCs and GSCs were maintained in stem cell media (SCM) (05702; StemCell)
supplemented with 20 ng/mL EGF (E4127; Sigma) and 10 ng/mL basic FGF
(F0291; Sigma). Differentiation assays were carried out by plating the in-
dicated cells in culture wells on coverslips precoated with 15 μg/mL poly-L-
ornithine (P3655; Sigma) and 1 μg/mL ﬁbronectin (F1141; Sigma); the cells
were incubated in SCM supplemented with 1% FBS or EN-StemA medium for
7–10 d, and the differentiation capacities were examined under either
a light or ﬂuorescence microscope (Nikon).
P19 cells were differentiated into postmitotic neuronal cells as described
previously (50). Brieﬂy, P19 cells were grown in αMEM with 10% FBS. Differ-
entiation was induced by transfer to medium containing αMEM, 5% FBS, and
0.5 μM all-trans retinoic acid (R-2625; Sigma Aldrich) in bacteriological Petri
dishes at a density of 105/cm2 to promote cell aggregation. After 2 d, cell
aggregates were transferred to fresh induction medium and cultured for an-
other 2 d. The cell aggregates were then trypsinized and were plated at
a density of 104/cm2 on tissue culture plates in αMEM plus 10% (vol/vol) FBS.
The tissue culture plates were coated previously overnight with 0.1 mg/mL
poly-L-lysine in 1.25% (wt/vol) boric acid/1.91% (wt/vol) sodium tetraborate
solution (1:1; pH 8.2), and washed three times with sterilized water. Two days
after plating, the medium was changed to Neurobasal-A medium (GIBCO)
with 1× B27 supplement (GIBCO) and maintained through the experiment.
Subcutaneous and Orthotopic Cell Injections. For s.c. injections, femalenudemice
(Charles River) aged 6–8 wk were anesthetized, and 10 million cells were injected
into each ﬂank of nude mice. Tumor sizes were obtained from average of the
measurements at three dimensions. For intracranial injections, female SCID mice
(Charles River) aged 6–8 wk were anesthetized and placed into stereotactic ap-
paratus equipped with a z axis (Stoelting). A small hole was bored in the skull 0.5
mmanterior and 3.0mm lateral to the bregma using a dental drill; 2 × 105 (Figs. 2
and 3; SI Appendix, Fig. S11) or 5 × 105 (SI Appendix, Figs. S9–11, S14, and S16)
cells in Hanks buffered salt solution were injected into the right caudate nucleus
3 mm below the surface of the brain using a 10-μL Hamilton syringe with an
unbeveled 30-gauge needle. The scalp was closed using a 9-mm Autoclip
Applier. Animals were followed for the development of neurological deﬁcits
every other day.Animals transplantedwith cells stably express luciferase activity
were monitored with imaging system Lumina II (Xenogen) every other day.
For doxycycline-induced expression, mice were injected and fed on regular
water for tumor to grow, and mice were fed on doxycycline water for 3 d. All
manipulations were performed with IACUC approval.
RNA-Binding Protein Immunoprecipitation–Microarray Proﬁling Analysis Poly-
some lysis buffer was prepared as previously described (29). Brieﬂy, 50 μL of
1 M Hepes, 500 μL of 1 M KCl, 25 μL of 1 M MgCl2, and 25 μL of Nonidet P-40
were added to 4.7 mL of RNase-DNase-free H2O. Fifty microliters of 1 M DTT,
12.5 μL of 100 U/mL RNase Out (Promega), and 200 μL of Protease inhibitor
mixture (Roche Complete Mini) were added at the time of use. Two WT
8-wk-old mouse brains were homogenized in 10 mL of lysis buffer. Tissue
lysate was precipitated, and A2BP1 antibody (Genscript)-coupled protein
A/G beads (Santa Cruz) were added to the supernatant, which was sub-
sequently incubated at 4 °C for 1 h. Beads were washed with lysis buffer
three times, and RNAs were extracted with the RNeasy kit (Qiagen) and
were subsequently proﬁled with mouse Exon Array (1.0 ST). RNA proﬁles
were analyzed with dCHIP software.
Scratching Assay. Cells were grown to subconﬂuence and then scratched with
a 200-μL tip. Cells were subsequently cultured for 22 h. The distance between
14526 | www.pnas.org/cgi/doi/10.1073/pnas.1308610110 Hu et al.
two borders of scratching was measured at 0 and 22 h. The distance of each
scratch was measured six times at different sizes and averaged.
Expression and shRNA Plasmids. ORFs of 71 candidate genes and the TPM1
gene were obtained from Open Biosystems and cloned into lentiviral
plasmids pLenti6.3-V5/Dest, pLenti6-Ubc-V5/Dest, and pLenti4/TO-V5/Dest.
Tet-O-FUW-Myt1L plasmid (24) was ordered from Addgene (Addgene
plasmid 27152). PLKO-based lentiviral shRNA plasmids targeting A2BP1
and Myt1L were obtained from the DF/HCC DNA Resource Core. The
targeting sequences are listed in SI Appendix, Table S6.
Chromatin immunoprecipitation analyses, the invasion assay, EMSA, and
the Luciferase reporter assay are described in SI Appendix, SI Materials
and Methods.
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